SCHEMBL4026769

SCHEMBL4026769

CN(C)C(=O)c1ccc(N)c(-c2nnn[nH]2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.36
JAK3 P52333 1/20 0.36
MAP4K1 Q92918 3/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
LRRK2 Q5S007 1/20 0.34
CHEK2 O96017 1/20 0.34
CDK1 P06493 1/20 0.34
CDK2 P24941 1/20 0.34
MKNK1 Q9BUB5 1/20 0.34
MKNK2 Q9HBH9 1/20 0.34
NCOA1 Q15788 1/20 0.33
NCOA3 Q9Y6Q9 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
PDE9A O76083 1/20 0.33
PDK2 Q15119 2/20 0.33
TNF P01375 1/20 0.32
MYLK Q15746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4029897 0.90 LRRK2 (0.44) MAPTMAP4K1ALDH1A1HPGDLRRK2
SCHEMBL4021504 0.86 HPGD (0.42) MAPTALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL4029711 0.85 PIN1 (0.35) PDK2
SCHEMBL27622304 0.85 PIN1 (0.35) PDK2
SCHEMBL4022857 0.81 THRB (0.39) HPGDSMN1; SMN2PDK2
SCHEMBL4029655 0.77 MAPT (0.50) MAPTALDH1A1HPGDLRRK2CHEK2
SCHEMBL4029918 0.76 IP6K1 (0.38) SMN1; SMN2
SCHEMBL4029915 0.76 IP6K1 (0.38) SMN1; SMN2
SCHEMBL4025859 0.76 MKNK1 (0.44) CHEK2MKNK1MKNK2FYN
SCHEMBL24690187 0.75 LRRK2 (0.42) MAPTALDH1A1HPGDSMN1; SMN2LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537075-B1 DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH AS (DK) 2009-07-01 EP disclosed
US-20060160856-A1 Diarylurea derivatives and their use as chloride channel blockers NEUROSEARCH A/S (DK) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160856-A1 Diarylurea derivatives and their use as chloride channel blockers KIT, ORAI1, CACNA1C MAPT 4510/4885JAK3 3005/4885MAP4K1 2455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.